Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Thorac Oncol. 2012 Sep;7(9):1361–1368. doi: 10.1097/JTO.0b013e318260e106

Table 4.

Survival Prognostic Factors and Prediction Models for Non-Small Cell Lung Cancer from Five Retrospective Analyses

ECOG
Finkelstein, 19865 		SWOG
Albain, 19916 		ELCWP
Paesmans, 19957 		ECOG
Hoang, 20051 		ECOG
Hoang, 2011
Database       2 phase III
(EST 2575 & 1581)		    5 phase III
    9 phase II		    3 phase III
    4 phase II		         2 phase III
(ECOG 1592 & 1594)		   1 phase III
(ECOG 4599)
Patient number           893         2531         1052      1436         850
Disease stage Metastatic Locally advanced
or metastatic		 Unresectable I-IV Wet IIIB, IV,
or recurrent		 Wet IIIB, IV,
or recurrent
Histology Any NSCLC histology Any NSCLC histology Any NSCLC histology Any NSCLC histology Non-squamous NSCLC
Line of treatment First-line First-line
or previously treated		 First-line
or previously treated		 First-line First-line
Chemotherapy
regimens		 Various older platin
and non-platin based
regimens		 Various older platin
and non-platin based
regimens; mono
versus combined		 Various platin-based,
second-generation
regimens; mono
versus combined		 Platin-based, third-
generation doublets		 Paclitaxel, carboplatin
with or without
bevacizumab
Survival
   Median, months
   1-year, %
   2-year, %
   < 6
       19
        4
   5.1
   16
    -
    7
    -
   7.4
     8.2
     33
     11
      10.3/12.3*
        44/51*
        15/23*
No. of factors
analyzed		     36    15 (not all patients)    23      27     26
Independent
negative survival
prognostic factors
identified from
multivariate
analyses		 1. Lower PS (1–2)
2. Bone metastasis
3. Male gender
4. Weight loss
5. Subcutaneous
metastasis
6. Large cell
carcinoma
7. Shoulder/arm pain
8. Liver metastasis		 All patients:
1. Lower PS (≥2)
2. Non-platin drugs
3. Male gender
4. Age < 70
PS 0–1 patients:
1. Hb < 11
2. Abnormal LDH
3. Abnormal calcium
4. ≥2 metastatic
lesions
5. Non-platin drugs		 1. Stage IV (vs. earlier
stages)
2. Lower PS (≤70)
3. Increased WBC
4. Skin metastasis
5. Increased calcium
6. Abnormal ANC
7. Age > 60
8. Male gender		 1. Skin metastasis
2. Lower PS (1–2)
3. Loss of appetite
4. Liver metastasis
5. ≥4 metastatic sites
6. No prior lung surgery		 1. Skin metastasis
2. Low BMI <18.5
3. Increased LDH
4. Adrenal metastasis
5. Lower PS (1)
6. Low serum albumin
7. Male gender
8. Bone metastasis
9. LCC/NOS histology
10. Mediastinal nodal
metastasis
11. No bevacizumab
(PC alone)
Survival prediction
model or prognostic
subgroups		 Discriminant function
requiring calculation to
predict if an individual
will survive > 1 year or
not		 Three prognostic
subgroups based on
recursive partitioning
and amalgamation		 Four prognostic
subgroups with
different 1- and 2-year
survival, based on
recursive partitioning
and amalgamation		 Nomogram with a
scoring system to
predict 1-and 2-year
survival probability of
individual patients		 Nomogram with a
scoring system to predict
probability of 1-year
survival and 6-month
PFS of individual
patients
*

without bevacizumab/with bevacizumab

Abbreviations: ECOG, Eastern Cooperative oncology Group; SWOG, Southwest Oncology Group; ELCWP, European Lung Cancer Working Party; PS, performance status; Hb, hemoglobin; LDH, lactic dehydrogenase; WBC, white blood count; ANC, absolute neutrophil count; BMI, body mass index; LCC, large cell carcinoma; NOS, not otherwise specified.